glp 1 and neuroinflammation The Impact of GLP-1 Receptor Agonists on Ocular Disease The role of microglial GLP-1R

Recently, genome editing therapies have predominantly targeted diseases with well-defined causative mutations, which affect only about 0.5% to 1% of the global population

11 CGMs provide robust data on blood sugar control, and therefore may contribute to improved glucose control, especially for patients with variable glucose, as seen in gastroparesis

They are generally not recommended for patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), those who are pregnant or breastfeeding or planning pregnancy, patients with a known allergy to the medication, severe gastroparesis or serious digestive motility disorders, active pancreatitis or significant pancreatitis history, serious gallbladder disease, certain kidney conditions, or active eating disorder concerns

That leaves open questions about long-term and real-world risks

By reducing hunger signals to the brain, slowing digestion so food stays in the stomach longer, and improving insulin sensitivity, these drugs make it easier to eat less, feel full sooner, and maintain more stable blood sugar levels

If about 40% of them have obesity, as statistics suggest, that translates into 22 million people who may be able to take part in the new program depending on their weight and health